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Abstract
Objective:  The  aim  of  this  study  was  to  evaluate  the  effects  of  deep  brain  stimulation  of  the
subthalamic  nucleus  (DBS-SN)  on  cognitive  function  in  patients  with  Parkinson’s  disease  (PD)  5
years after  surgery.
Material  and  methods:  We  conducted  a  prospective  study  including  50  patients  with  PD  who
underwent  DBS-SN  (62.5%  were  men;  mean  age  of  62.2  ±  8.2  years;  mean  progression  time
of 14.1  ±  6.3  years).  All  patients  were  assessed  before  the  procedure  and  at  one  year  after
surgery;  40  patients  were  further  followed  up  until  the  5-year  mark.  Follow-up  assessments
included  the  following  neuropsychological  tests:  Mini-Mental  State  Examination  (MMSE),  Mattis
Dementia  Rating  Scale  (MDRS),  letter-number  sequencing  of  the  WAIS-III  (WAIS-III-LN),  clock-
drawing  test,  Rey  auditory  verbal  learning  test  (RAVLT),  Benton  Visual  Retention  Test  (BVRT),
Judgment  of  Line  Orientation  (JLO)  test,  FAS  Phonemic  Verbal  Fluency  Test,  Stroop  test,  and
the Montgomery—Asberg  Depression  Rating  Scale  (MADRS).
Results:  Patients  were  found  to  score  lower  on  the  MMSE  (−0.89%),  clock-drawing  test
(−2.61%), MDRS  (−1.72%),  and  especially  phonemic  (−13.28%)  and  sematic  verbal  fluency  tests
(−12.40%) at  one  year  after  surgery.  Delayed  recall  on  the  RAVLT  worsened  one  year  after  the
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procedure  (−10.12%).  At  5  years,  impairment  affected  mainly  verbal  fluency;  scores  decreased
an additional  16.10%  and  16.60%  in  semantic  and  phonemic  verbal  fluency,  respectively.  Mod-
erate decreases  were  observed  in  immediate  recall  (−16.87%),  WAIS-III-LN  (−16.67%),  and  JLO
test (−11.56%).
Discussion:  In  our  sample,  DBS-SN  did  not  result  in  global  cognitive  impairment  5  years  after
surgery. Verbal  function  was  found  to  be  significantly  impaired  one  year  after  the  procedure.
Impaired learning  and  visuospatial  function  may  be  attributed  to  degeneration  associated  with
PD.
© 2017  Sociedad  Espan˜ola  de  Neurolog´ıa.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an  open
access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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Impacto  de  la  estimulación  subtalámica  a  largo  plazo  sobre  la  situación  cognitiva  de
los  pacientes  con  enfermedad  de  Parkinson  avanzada
Resumen
Objetivo:  El  objetivo  es  evaluar  los  efectos  de  la  estimulación  cerebral  profunda  del  núcleo
subtalámico  bilateral  (STN-DBS)  sobre  el  estado  cognitivo  de  los  pacientes  con  enfermedad  de
Parkinson 5  an˜os  después  de  la  cirugía.
Materiales  y  métodos:  En  este  estudio  prospectivo  se  incluyeron  50  pacientes  con  enfer-
medad de  Parkinson  (62,5%  hombres,  edad  media  62,2  ±  8,2  an˜os  y  duración  de  la  enfermedad
14,1 ±  6,3  an˜os)  sometidos  a  STN-DBS.  Todos  los  pacientes  fueron  evaluados  preoperatoriamente
y un  an˜o  después  de  la  cirugía,  y  40  pacientes  fueron  seguidos  hasta  5  an˜os.  En  cada  visita  se
realizaron las  siguientes  evaluaciones  neuropsicológicas:  Mini-Mental  State  Examination,  Mat-
tis Dementia  Rating  Scale  (MDRS),  test  de  secuencias  números-letras  de  WAIS  III-LN,  Prueba
de dibujo  de  reloj,  Prueba  de  aprendizaje  verbal  auditivo  Rey,  la  Prueba  de  retención  visual
de Benton,  la  Prueba  de  juicio  de  orientación  de  línea  de  Benton,  la  fluidez  verbal  fonética  y
semántica,  la  Prueba  Stroop  y  la  Escala  de  clasificación  de  depresión  de  Montgomery-Asberg.
Resultados:  Anualmente  se  observaron  reducciones  en  la  puntación  de  Mini-Mental  State  Exam-
ination (−0,89%),  Prueba  del  dibujo  de  reloj  (−2,61%)  y  MDRS  (−1,72%),  fueron  más  marcados
tanto para  la  fluidez  verbal  fonética  (−13,28%)  como  semántica  (−12,40%).  Para  la  Prueba  de
aprendizaje  verbal  auditivo  Rey  observamos  un  deterioro  en  la  capacidad  de  recuerdo  diferido
(−10,12%) un  an˜o  después  de  la  cirugía.  A  los  5  an˜os  la  mayor  parte  del  deterioro  se  produjo  en
la fluidez  verbal,  con  reducciones  adicionales  de  16,10%  y  16,60%  para  la  fluidez  verbal  semán-
tica y  fonética,  respectivamente.  Se  observó  un  empeoramiento  más  moderado  del  recuerdo
inmediato  (−16,87%),  WAIS  III-LN  (−16,67%)  y  de  la  prueba  de  orientación  lineal  de  Benton
(−11,56%).
Discusión:  La  STN-DBS  no  condujo  a  deterioro  cognitivo  global  a  los  5  an˜os  de  la  cirugía.  Hubo
un deterioro  significativo  en  la  función  verbal  desde  el  primer  an˜o  de  la  cirugía.  El  deterioro
de la  capacidad  de  aprendizaje  y  de  las  funciones  visuoespaciales  podría  atribuirse  al  propio
proceso degenerativo  de  la  enfermedad.
© 2017  Sociedad  Espan˜ola  de  Neurolog´ıa.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este  es  un
art´ıculo Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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eep  brain  stimulation  (DBS)  is  reported  to  be  effective
or  short-term  treatment  of  motor  symptoms  of  Parkinson’s
isease  (PD).  It  has  also  been  observed  to  reduce  dopamin-
rgic  drug  use,  resulting  in  fewer  motor  complications.1,2
o  significant  cognitive  deficits  have  been  observed  in
he  first  years  after  DBS,  with  the  exception  of  reduced
erbal  fluency,  probably  caused  by  the  surgery  to  the
ubthalamic  nucleus  (STN):  cognitive  alterations  are  less
requent  when  surgery  is  performed  on  the  internal  globus
allidus  (iGP).3—5 Cognitive  function  may  change  when
i
l
a
lulse  generators  are  turned  on,6,7 with  alterations  in
he  ability  to  inhibit  interference  (evaluated  with  the
nterference  version  of  the  Stroop  Color  and  Word  Test
SCWT]).6 As  mentioned  previously,  outcomes  may  vary
ccording  to  the  target  of  surgery.  According  to  several
tudies,  patients  receiving  DBS  in  the  STN  (STN-DBS)  per-
orm  more  poorly  in  conditional  associative  learning  tasks
han  those  receiving  iGP  stimulation.6 However,  STN-DBS
mproves  cognitive  flexibility,  according  to  neuropsycho-
ogical  test  results.6,8 Motor  and  cognitive  improvements
fter  the  intervention  result  in  greater  patient  quality  of
ife.9—11
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RLong-term  impact  of  subthalamic  stimulation  on  cognitive  fu
Little  is  known  about  the  long-term  course  of  motor
symptoms  in  patients  treated  with  DBS.  According  to  the
first  5-year  follow-up  studies  of  the  effects  of  DBS,  the  bene-
fits  of  treatment  are  partially  lost  during  the  first  years  after
surgery.12—15 Few  studies  have  analysed  the  impact  of  DBS  on
cognition  at  5  years.  One  study,  with  a  small  patient  sample,
reported  a  decline  in  verbal  fluency  and  abstract  reasoning
5  years  after  the  intervention.16 Other  studies  focusing  on
the  clinical  course  of  motor  function  report  cognitive  impair-
ment  at  5  years,  which  was  attributed  to  the  clinical  course
of  the  disease.14,15
The  purpose  of  this  study  was  to  evaluate  the  effects  of
DBS  on  cognitive  function  at  5  years  after  surgery,  and  to
compare  these  effects  against  the  degeneration  inherent  to
PD.
Material and methods
We  gathered  a  sample  of  50  patients  diagnosed  with  PD
according  to  the  United  Kingdom  Parkinson’s  Disease  Soci-
ety  Brain  Bank  criteria  (except  for  family  history  of  PD)  and
the  recommendations  of  the  Core  Assessment  Program  for
Surgical  Interventional  Therapies  in  Parkinson’s  disease.  All
patients  underwent  tetrapolar  electrode  implantation  (3389
DBS,  Medtronic;  Minneapolis,  USA)  in  both  STN.  The  inter-
vention  was  performed  at  the  movement  disorders  unit  of
Hospital  Universitario  de  Cruces  in  Baracaldo  (Spain).  Mean
age  (standard  deviation  [SD])  at  the  time  of  surgery  was  62.2
(8.2)  years,  with  a  mean  disease  duration  of  14.1  (6.3)  years.
The  sample  included  32  men  (64%)  and  18  women  (36%).
Exclusion  criteria  were  as  follows:  diagnosis  of  dementia,
clinical  manifestations  suggestive  of  atypical  parkinsonism,
concomitant  diseases  contraindicating  surgery,  and  severe
psychiatric  disorders.  Patients  undergoing  unilateral  implan-
tation,  those  undergoing  surgery  to  the  iGP,  and  patients
treated  at  other  centres  were  excluded  from  our  sample.  We
also  excluded  19  patients  who  had  been  evaluated  accord-
ing  to  a  different  neuropsychological  protocol  to  that  used
in  our  study,  whose  design  is  based  on  published  evidence
and  the  consensus  of  our  surgery  team.
We  recorded  birth  date,  date  of  PD  diagnosis  and  onset  of
dopaminergic  therapy,  education  level,  medical  and  psychi-
atric  history,  and  levodopa  equivalent  dose.  We  calculated
the  levodopa  equivalent  daily  dose  (LEDD)17 for  all  dopamin-
ergic  drugs  (Table  1).  All  patients  were  evaluated  with  the
Unified  Parkinson’s  Disease  Rating  Scale  (UPDRS  I-IV).  Quality
Table  1  Levodopa  equivalent  daily  dose17 (equivalent  to
100 mg  levodopa)  for  different  dopaminergic  drugs.
Drug  Dose  (mg)
Extended-release  levodopa  133
Levodopa  +  entacapone  75
Ropinirole  5
Rotigotine  5
Pramipexole  1
Amantadine  100
Apomorphine  10
Rasagiline  1
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f  life  was  evaluated  with  the  Parkinson’s  Disease  Question-
aire  (PDQ-39)  during  ‘‘drug-on’’  periods  at  baseline  (before
urgery)  and  during  ‘‘drug-on/DBS-on’’  periods  at  follow-up
pulse  generators  turned  on).  Patients  used  diaries  to  record
he  duration  of  ‘‘off’’  periods.
Surgery  was  performed  according  to  the  protocol  previ-
usly  described  in  the  literature.9,13
europsychological  study
aseline  neuropsychological  assessments  were  performed  2
onths  before  surgery.  Patients  were  prospectively  eval-
ated  12  and  60  months  after  neurosurgery.  All  patients
ere  evaluated  during  ‘‘drug-on’’  periods  before  surgery
nd  during  ‘‘drug-on/DBS-on’’  periods  at  postoperative
ollow-up  consultations.  All  assessments  were  performed  by
he  same  neuropsychologist.  The  neuropsychological  assess-
ent  is  structured  in  2  parts:  a  semi-structured  interview
ith  the  patient  and  an  informant,  and  a  neuropsycholog-
cal  test  battery  designed  to  evaluate  multiple  cognitive
omains  which  are  frequently  impaired  in  patients  with
D.  Patients  completed  cognitive  tests  including  the  Mini-
ental  State  Examination  (MMSE)  and  the  Mattis  Dementia
ating  Scale  2  (MDRS-2),  which  includes  subscales  testing
ttention,  memory,  initiation/perseveration,  construction,
nd  conceptualisation.  Memory  was  evaluated  with  2  addi-
ional  tests:  the  Rey  Auditory  Verbal  Learning  Test  (RAVLT),
hich  evaluates  short-term  auditory-verbal  memory  (imme-
iate  and  delayed  recall  trials),  and  the  Benton  Visual
etention  Test  (BVRT),  for  visual  memory.  The  SCWT  was
sed  to  measure  processing  speed,  selective  attention,
nd  cognitive  flexibility.  The  letter-number  sequencing  sub-
est  of  the  Wechsler  Adult  Intelligence  Scale  (WAIS-III)  was
dministered  to  evaluate  attention  and  working  memory.
isuospatial  ability  was  evaluated  with  the  Benton  Judgment
f  Line  Orientation  (JLO)  test  and  the  clock-drawing  test.  To
ssess  phonemic  and  semantic  verbal  fluency,  patients  were
sked  to  produce  as  many  words  beginning  with  the  letter
‘p’’  and  to  name  as  many  animals  as  possible,  with  one
inute  for  each  category.  In  all  tests,  higher  scores  reflect
etter  performance.  The  Montgomery—Asberg  Depression
ating  Scale  (MADRS)  was  administered  at  each  consultation
o  evaluate  depression.
Given  the  inappropriateness  on  ethical  grounds  of  includ-
ng  a  control  group  in  studies  evaluating  surgery  outcomes,
e  retrospectively  selected  a group  of  47  patients  with  PD
mean  age  [SD]  of  66.1  years  [6.1],  with  a  mean  disease  dura-
ion  of  8.8  years  [4.4]),  who  were  followed  up  for  5  years  and
ere  eligible  for  DBS  according  to  the  neurological  criteria
sed,  but  who  did  not  undergo  the  procedure  for  various
easons  (patient  not  willing  to  undergo  surgery,  concomi-
ant  diseases,  etc.).  Despite  its  methodological  limitations,
his  design  gives  an  idea  of  the  incidence  of  dementia  over
he  same  period  of  time  in  a  group  of  patients  with  simi-
ar  characteristics  to  those  of  our  patients  receiving  DBS.
e  analysed  the  incidence  of  dementia  based  on  the  cri-eria  established  in  the  Diagnostic  and  Statistical  Manual  of
ental  Disorders  (DSM-IV),  performance  in  assessment  scales
mainly  the  UPDRS  I  and  the  MMSE),  and  interviews  with
amily  members.
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nformed  consent
efore  undergoing  DBS,  patients  read  and  signed  informed
onsent  forms  approved  by  the  local  research  ethics  com-
ittee,  with  family  members  acting  as  witnesses.
tatistical  analysis
uantitative  data  are  expressed  as  means  (SD)  and  qualita-
ive  variables  as  percentages.  Given  the  small  size  of  our
ample,  non-parametric  tests  were  used  to  compare  means
Friedman  and  Wilcoxon  tests).  To  analyse  the  predictive
apacity  of  MDRS-2  scores  for  detecting  dementia  at  5  years
cut-off  point  <123),  we  used  bivariate  correlations  (Pearson
orrelation  coefficient),  stepwise  linear  regression,  and  ROC
a
e
p
a
Table  2  Baseline  characteristics  of  the  50  patients  undergoing  su
years) and  the  47  patients  of  the  comparison  group  (including  caus
Variables  
Patients
undergoing  surgery
n  =  50
Age  at  the  time  of
surgery  (years)
Sex (women/men)  
Disease  duration  before
surgery  (years)
Patients  lost  to  follow-up  
Cause  of  loss  to
follow-up
Patients in  the
comparison  group
n =  47
Age  at  first  consultation
(years)
Sex (women/men)  
Disease  duration  until
first  consultation  (years)
Patients  lost  to  follow-up  
Reasons  for  not
undergoing  surgery
COPD: chronic obstructive pulmonary disease; MCI: mild cognitive im
failure.M.  Acera  et  al.
urves  to  establish  scaled  scores  with  higher  sensitivity  for
ementia  screening.  Statistical  analysis  was  performed  using
he  SPSS  statistics  software,  version  20.0  (IBM;  Armonk,  NY,
SA).
esults
ighty  percent  of  patients  undergoing  DBS  were  evaluated
 years  after  the  procedure;  the  remaining  20%  were  lost  to
ollow-up:  4  died,  5  presented  concomitant  diseases  pre-
enting  assessment,  and  the  remaining  patient  was  not
ssessed  due  to  ineffectiveness  of  surgery  (the  pulse  gen-
rator  and  electrodes  were  removed)  (Table  2).  Forty-eight
atients  were  evaluated  at  one  year,  and  40  patients  were
ssessed  5  years  after  the  procedure.
rgery  (including  causes  of  loss  to  follow-up  during  the  first  5
e  of  loss  to  follow-up  and  reason  for  not  undergoing  surgery).
Mean  (SD)  or  n  (%)
62.2  (8.2)
18  (36%)/32  (64%)
14.1  (6.3)
10  (20%)
Death:  4  (8%)
Surgery  not  effective:  1  (2%)
Systemic  disease:  3  (6%)
Stroke:  1  (2%)
Electrode  removal  due  to  infection:  1  (2%)
66.1  (6.1)
24  (51%)/23  (49%)
8.8  (4.4)
Death:  9  (16%).  Causes:
Head  trauma/brain  haematoma  (2)
Choking  (1)
Urinary  sepsis  (2)
Pulmonary  embolism  (1)
Kidney  failure  (1)
Stroke  (1)
Pneumonia  (1)
Patient  refused  surgery  or  was  not  initially  referred  to  the
MDU:  23
Heart  disease  contraindicating  surgery:  9
Neoplasia:  3
Severe  COPD:  2
Poor  treatment  adherence:  1
Kidney  failure:  2
MCI  and  drug-induced  hallucinations  (not  meeting  criteria
for dementia):  4
Severe  PAF  and  haemodynamic  instability:  1
Severe  atheromatosis:  2
pairment; MDU: movement disorders unit; PAF: pure autonomic
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Motor  function  and  performance  in  activities  of
daily living
UPDRS  I-IV  scores  are  shown  in  Table  3.  Patients  were  rela-
tively  young,  with  a  mean  age  (SD)  of  62.2  years  (8.2)  at  the
time  of  surgery,  although  with  long  disease  progression  times
(14.1  years  [6.3]).  At  baseline,  a  supramaximal  dose  of  lev-
odopa  achieved  a  maximum  improvement  of  56%  in  UPDRS
III  scores.  We  observed  significant  differences  between  pre-
and  postoperative  UPDRS  III  ratings,  with  scores  showing
improvements  of  34%  at  year  one  and  22%  5  years  after
surgery  in  ‘‘drug-off/DBS-on’’  periods  (Table  3).  However,
during  ‘‘drug-on/DBS-on’’  periods,  UPDRS  III  scores  wors-
ened  by  37.60%  5 years  after  surgery  compared  to  baseline
and  1-year  scores,  which  were  similar  (Table  3).  We  observed
a  significant  decrease  in  the  duration  of  ‘‘off’’  periods  one
year  after  the  intervention;  this  improvement  was  still  par-
tially  visible  at  5  years  (Table  3).
LEDD  decreased  significantly  at  one  year  (−25.41%)  and
5  years  (−19.34%)  after  surgery  compared  to  baseline.
Only  one  patient  received  advanced  PD  treatment  during
the  5-year  follow-up  period  (apomorphine  infusion).  The
associated  complications  (UPDRS  IV)  also  showed  marked,
sustained  improvements  (−55.83%  at  one  year  and  −47.64%
at  5  years).  These  changes  had  a  significant  positive  impact
on  performance  in  activities  of  daily  living  (UPDRS  II),  which
was  more  marked  one  year  after  surgery  (−43.09%)  than  at
5  years  (−26.28%).  However,  these  improvements  are  poorly
reflected  in  quality  of  life  (PDQ-39)  at  5  years  after  surgery,
with  nearly  imperceptible  changes  compared  to  baseline
(−3.49%);  quality  of  life  worsened  between  the  first  and  the
fifth  year  of  follow-up  (+33.90%)  (Table  3).
Neuropsychological  test  results  at  one  year  of
follow-up
Assessment  scores  for  global  cognitive  function  showed  non-
significant  reductions  one  year  after  surgery  (MMSE:  −0.89%;
clock-drawing  test:  −2.61%;  MDRS-2:  −1.72%)  (Table  4).
Visuospatial  ability  (JLO  test)  remained  virtually  unchanged
one  year  after  surgery.  Patients  showed  impaired  learning
during  the  SCWT:  4  patients  were  unable  to  complete  the
test  at  baseline,  compared  to  11  patients  at  one  year  and
11  patients  at  5  years.  The  remaining  patients  showed  no
significant  neuropsychological  impairment  (Table  4).  Both
phonemic  (−13.28%)  and  semantic  verbal  fluency  (−12.40%)
worsened  significantly  in  the  surgery  group.  The  RAVLT
revealed  poorer  delayed  recall  at  one  year  (−10.12%);
immediate  recall  worsened  to  a  lesser  extent  (−5.22%).
Working  memory  (letter-number  sequencing  subtest  of  the
WAIS-III)  showed  non-significant  improvements.  Mood  also
improved:  MADRS  scores  improved  by  19.67%,  reflecting  less
severe  depressive  symptoms  (Table  4).
Neuropsychological  test  results  at  5  years  of
follow-upGlobal  cognitive  function  was  poorer  at  5  years  after
surgery  (MMSE:  −7.54%;  clock-drawing  test:  −9.61%;  MDRS-
2:  −5.73%).  Decreases  were  most  marked  in  verbal  fluency.
From  year  one  to  year  5,  semantic  and  phonemic  fluency
t
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ecreased  an  additional  16.10%  and  16.6%,  respectively.
ognitive  function  was  considerably  worse  at  5  years
−26.50%  in  semantic  fluency,  −27.46%  in  phonemic  ver-
al  fluency).  Changes  were  most  marked  in  learning  ability
RAVLT,  immediate  recall:  −16.87%)  and  working  memory
WAIS-III,  letter-number  sequencing  subtest:  16.67%).  Visu-
spatial  ability  was  also  considerably  impaired  compared  to
ollow-up  year  one  (−11.56%).
A  year  after  surgery,  2  patients  (4%)  scored  ≤  26  on  the
MSE,  compared  to  9  patients  (22%)  at  5  years.  None  of  the
atients  scored  below  20  points  at  5  years  after  surgery.  On
DRS,  10  and  14  patients  (21%  and  35%)  scored  below  the
ut-off  score  (130  points)  at  one  and  5  years,  respectively.
he  lowest  MDRS-2  score  of  any  patient  in  our  sample  was  81
oints.  Depressive  symptoms  (MADRS)  improved  during  the
rst  year  following  surgery  but  returned  to  baseline  values
t  5  years  (Table  4).
redictors  of  cognitive  impairment
e  observed  a  strong  correlation  between  baseline  and  5-
ear  follow-up  MDRS-2  scores  (correlation  coefficient  0.78;
 <  .001).  Stepwise  linear  regression,  with  MDRS-2  score  at  5
ears  as  the  dependent  variable  and  all  baseline  quantitative
ariables  (age;  progression  time;  scores  on  the  UPDRS-I-IV,
EDD,  MDRS-2,  MMSE,  clock-drawing  test,  WAIS-III,  phone-
ic  verbal  fluency  test,  SCWT)  as  independent  variables,
dentified  baseline  MDRS-2  score  as  the  only  predictive  vari-
ble.  ROC  curves  for  the  event  ‘‘MDRS-2  score  <  123  (cut-off
oint)  at  5  years’’  show  that  baseline  MDRS-2  scores  above
30  had  23%  sensitivity  and  baseline  MDRS-2  scores  above
37  had  0%  sensitivity  for  predicting  dementia  at  5  years
area  under  the  ROC  curve:  0.15;  P  <  .001).
esults  from  the  comparison  group
ine  of  the  47  patients  included  in  the  comparison  group
19%)  died  within  5  years  of  follow-up;  they  had  a  mean  age
SD)  of  73.4  years  (4.5)  and  a  mean  disease  progression  time
f  13.1  years  (4.8).  Eighteen  patients  (38.3%)  met  DSM-IV
riteria  for  dementia  at  5  years  of  follow-up;  this  group  had
 mean  age  of  71.3  years  (4.6).  Table  2  shows  the  reasons
hat  DBS  was  not  administered  to  these  patients.
iscussion
he  results  of  our  long-term  follow-up  study  reveal  a  slight
ecrease  in  MDRS-2,  MMSE,  and  clock-drawing  test  scores
n  5-year  survivors;  these  decreases  are  not  attributable  to
TN-DBS  since  worsening  mostly  occurred  between  years  one
nd  5  of  follow-up.  During  that  period,  a  significant  increase
as  observed  in  the  number  of  patients  scoring  below  26  on
he  MMSE.  The  percentage  of  patients  with  cognitive  impair-
ent  increased  when  more  sensitive  scales,  such  as  the
DRS-2,  were  used.  Thus,  35%  (n  =  14)  scored  below  130  on
he  MDRS-2  scale  at  5  years  of  follow-up.  Interestingly,  21%
f  patients  already  scored  below  130  at  follow-up  year  one,
ue  to  poor  performance  in  the  initiation/perseveration  sub-
cale.  Other  studies  using  the  MDRS-2  have  also  reported  a
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Table  3  Scores  for  the  different  parts  of  the  Unified  Parkinson’s  Disease  Rating  Scale.
Variable  Baseline  At  1  year  Baseline—1  year%  (P)  At  5  years  Baseline—5  years
% (P)
1  year—5  years
%  (P)
UPDRS  I  2.62  (2.38)  2.40  (2.09)  −8.40%  (ns)  3.20  (2.42)  +22.14%  (ns)  +33.33%  (.024)
UPDRS II  (‘‘off’’)  18.40  (5.44)  10.47  (5.35)  −43.09%  (<.001)  13.49  (8.23)  −26.68%  (<.001)  +28.84%  (.006)
UPDRS II  (‘‘on’’)  4.93  (4.24)  4.84  (4.32)  −1.82%  (ns)  9.97  (6.92)  +102.23%  (<.001)  +105.99%  (<.001)
UPDRS III  (‘‘off’’)  38.68  (9.09)  25.53  (9.54)  −34.00%  (<.001)  30.47  (11.54)  −21.22%  (<.001)  +19.34%  (<.001)
UPDRS III  (‘‘on’’)  17.42  (7.16)  16.76  (7.23)  −3.79%  (ns)  23.97  (10.59)  +37.60%  (<.001)  +43.02%  (<.001)
UPDRS IV  8.06  (3.53)  3.56  (3.09)  −55.83%  (<.001)  4.22  (2.87)  −47.64%  (<.001)  +18.54%  (ns)
LEDD 887.44  (412.86)  661.97  (413.37)  −25.41%  (<.001)  715.78  (427.76)  −19.34%  (.032)  +8.13%  (ns)
PDQ-39 Summary
Indexa
38.10  (13.03)  27.46  (14.61)  −27.93%  (<.001)  36.77  (15.43)  −3.49%  (ns)  +33.90  (<.001)
Duration of  ‘‘off’’
state  (hours/day)b
5.38  (3.17)  0.72  (2.19)  −86.61%  (<.001)  2.85  (4.27)  −47.02%  (<.001)  +74.73%  (<.001)
a The PDQ-39 was used to evaluate quality of life.
b Data obtained from patient diaries.
LEDD: levodopa equivalent daily dose; ns: not significant; PDQ-39: 39-item Parkinson’s Disease Questionnaire; UPDRS: Unified Parkinson’s Disease Rating Scale.
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Table  4  Scores  on  scales  measuring  cognitive  function  and  evaluating  depressive  symptoms  at  baseline,  at  one  year,  and  at  5  years  of  surgery.
Variable Domain Range
(cut-off
point for
dementia)
Baseline At 1 year Baseline—1 year
% (P)
At 5 years Baseline—5 years
% (P)
1 year—5 years
% (P)
MMSE Global cognitive
function
0-30
(24)
29.17 (1.26) 28.91 (1.64) −0.89% (ns) 26.97 (2.95) −7.54% (<.001) −6.71% (<.001)
Clock drawing test Global cognitive
function
0-10
(6)
8.43 (1.68) 8.21 (2.41) −2.61% (ns) 7.62 (2.18) −9.61% (.024) −7.19% (.033)
Semantic verbal
fluency
Verbal fluency < 10 13.47 (5.13) 11.80 (6.20) −12.40% (.007) 9.90 (6.37) −26.50% (<.001) −16.10% (<.001)
Phonemic verbal
fluency
Verbal fluency < 10 17.04 (6.29) 14.82 (5.54) −13.28% (.007) 12.36 (6.76) −27.46% (<.001) −16.60% (<.001)
MDRS-2 Global cognitive
function
0-144
(123)
132.20 (7.96) 129.93 (11.75) −1.72% (.051) 124.62 (17.03) −5.73% (<.001) −4.09% (.006)
MDRS-2 Attention Attention 0-37
(32)
34.71 (2.00) 34.82 (2.90) +0.32% (ns) 33.90 (2.62) −2.33% (ns) −2.64% (.007)
MDRS-2 Initia-
tion/perseveration
Initiation/
perseveration
0-37
(29)
34.96 (3.07) 32.80 (4.47) −6.18% (.006) 31.53 (5.74) −9.81% (<.001) −3.87% (.041)
MDRS-2
Construction
Constructional
praxis
0-6
(4)
5.84 (0.56) 5.60 (1.09) −4.10% (.062) 5.27 (1.43) −9.76% (<.016) −5.89% (.068)
MDRS-2
Conceptualisation
Conceptualisation
(abstract
reasoning)
0-39
(32)
35.04 (4.42) 35.51 (3.95) +1.34% (ns) 34.32 (5.73) −2.05% (ns) −3.35% (.045)
MDRS-2 Memory Memory 0-25
(19)
21.64 (2.72) 21.91 (3.40) +1.25% (ns) 20.52 (4.49) −5.17% (.046) −6.34% (.025)
RAVLT Immediate
recall
Immediate or
short-term
memory
Women 49.4
(SD: 7.2)
Men 37.6
(SD: 9.8)
38.66 (10.20) 36.64 (9.81) −5.22% (.035) 30.46 (12.07) −21.29% (<.001) −16.87% (.023)
RAVLT Delayed
recall
Long-term
memory
Women 10.2
(SD: 2.5)
Men 6.8 (SD:
3.7)
7.61 (3.29) 6.84 (2.84) −10.12% (.063) 6.44 (4.11) −15.37% (.005) −5.85% (ns)
SCWT (colour-word
task)
Capacity to
inhibit
interference
50 (SD: 11) 43.61 (12.34) 41.97 (12.82) −3.76% (ns) 41.80 (13.17) −4.15% (ns) −0.39% (ns)
JLO Visuospatial
ability
0-30
(21)
21.43 (6.31) 21.55 (6.01) +0.60% (ns) 19.06 (6.80) −11.06% (.041) −11.56% (.002)
WAIS-III
Letter-number
sequencing
Working memory 55-69
6 (2)
7.17 (2.97) 7.80 (3.20) +8.79% (ns) 6.50 (3.25) −9.34% (ns) −16.67% (.014)
MADRS Depression 0-60
(> 10)
13.06 (7.04) 10.49 (8.64) +19.67% (.024) 12.03 (9.21) +7.88% (ns) −14.68% (ns)
JLO: Benton Judgment of Line Orientation; MADRS: Montgomery—Asberg Depression Rating Scale; MDRS: Mattis Dementia Rating Scale; MMSE: Mini-Mental State Examination; ns: not
significant; RAVLT: Rey Auditory Verbal Learning Test; SCWT: Stroop Color and Word Test; SD: standard deviation.
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imilar  decrease  at  5  years  after  surgery.14,15 In  a  recent
tudy  with  a  shorter  follow-up  period  (3  years),  14%  of
atients  scored  below  130  on  the  MDRS-2.18 In  another
tudy,  however,  28%  of  patients  developed  dementia  (DSM-
V  criteria)  during  the  3-year  follow-up  period.19 Fasano
t  al.20 studied  32  consecutive  patients  undergoing  STN-
BS,  observing  a  slight  decline  in  cognitive  function  8  years
fter  surgery,  mainly  in  abstract  reasoning  and  executive
unction.  Verbal  fluency  was  the  most  severely  affected  cog-
itive  domain.  However,  only  20  patients  were  evaluated  at
 years;  furthermore,  the  patients  included  were  relatively
oung,  with  a  mean  age  (SD)  of  56.9  years  (7.2).
In  our  study,  38.3%  of  patients  from  the  comparison  group
et  the  DSM-IV  diagnostic  criteria  for  dementia  at  5  years  of
ollow-up.  Dementia  was  defined  differently  in  the  DBS  and
omparison  groups  since  the  study  was  based  on  daily  clinical
ractice;  however,  we  may  hypothesise  that  the  incidence  of
ementia  (DSM-IV  criteria)  in  the  study  group  at  5  years  was
imilar  to  that  of  the  comparison  group.  Other  studies  report
ariations  in  the  estimated  incidence  of  dementia  in  patients
ith  PD,  with  similar  ranges  to  those  reported  in  studies
ncluding  patients  receiving  medical  treatment.21 Little  is
nown  about  the  impact  of  mild  cognitive  impairment  on
BS  outcomes  in  patients  with  PD.  In  a  recent  study,  pres-
nce  of  mild  cognitive  impairment  was  not  found  to  affect
verall  DBS  outcomes.  However,  impairment  of  certain  cog-
itive  domains  had  a  more  deleterious  effect;  visuospatial
mpairment,  for  example,  was  predictive  of  poorer  surgi-
al  outcomes.22 In  our  study,  none  of  the  patients  scoring
ver  137  on  the  MDRS-2  at  baseline  scored  below  123  at  5
ears.  Only  23%  of  those  scoring  over  130  showed  cognitive
mpairment  5  years  after  surgery.  According  to  the  MDRS-2,
onstruction  and  initiation/perseveration  are  more  severely
mpaired  than  other  cognitive  domains.  Impairment  of  pos-
erior  cortical  functions  including  constructional  praxis,
isuospatial  function,  and  semantic  verbal  fluency  has  been
ound  to  predict  dementia  in  patients  with  PD.23 Our  study
evealed  significantly  impaired  semantic  and  phonemic  ver-
al  fluency  5  years  after  surgery.  However,  as  impairment
as  more  severe  one  year  after  the  procedure,  it  cannot  be
xplained  by  the  surgery  or  DBS  alone.3,16,24
Learning  ability  was  impaired  at  one  year  after  surgery,
s  the  RAVLT  results  show  (immediate  recall)3;  delayed
ecall  was  less  severely  affected.  SCWT  results  were  not
valuable  since  22%  and  27%  of  patients  were  unable
o  complete  the  test  at  one  and  5  years  after  surgery,
espectively.  The  patients  who  did  complete  the  test
howed  no  significant  impairment.  Other  studies  have  shown
hort-term  impairment  in  patients’  capacity  to  inhibit
nterference.8
Depressive  symptoms  may  worsen  following  STN-DBS;  this
ffect  depends  on  electrode  location,25 whether  dopaminer-
ic  treatment  is  reduced,13,26 and  patients’  expectations  of
urgery.  However,  most  studies  report  overall  improvements
n  depressive  symptoms.27 Our  study  showed  a  20%  improve-
ent  in  MADRS  scores  one  year  after  surgery;  improvements
ere  no  longer  observed  at  5  years,  however.
As  reported  by  other  studies,  motor  symptoms  improved
n  patients  undergoing  STN-DBS;  the  benefits  of  DBS
ersisted  at  5  years.13—15 Dopaminergic  drug  dose  was  signi-
cantly  reduced  and  motor  complications  were  significantly
ess  frequent  both  at  one  and  at  5  years.  However,  motorM.  Acera  et  al.
unction  worsened  during  ‘‘drug-on/DBS-on’’  periods  at  5
ears,13,15 especially  in  the  case  of  axial  symptoms.13,15,28,29
ur  sample  is  unusual  in  that  patients  were  younger  (mean
ge  [SD]  of  62.2  years  [8.2])  and  had  better  baseline  motor
unction  (mean  UPDRS-III  score  in  ‘‘off’’  periods:  38.68
9.09])  than  those  of  other  studies.14,15 Motor  function
mprovements  result  in  better  performance  in  activities  of
aily  living  (UPDRS-III)  at  one  (43.09%;  P  <  .001)  and  5  years
26.48%;  P  <  .001).  However,  no  improvements  in  quality  of
ife  (PDQ-39)  were  observed  5  years  after  surgery13;  this  may
artially  be  explained  by  worsening  of  axial  and  cognitive
ymptoms,  which  have  a  great  impact  on  quality  of  life.30,31
he  mortality  rate  observed  in  our  series  (8%)  is  as  expected
or  surgical  patients  in  our  sample’s  age  group.  Mortality  was
igher  in  the  comparison  group  (19%);  this  may  be  explained
y  the  fact  that  some  patients  were  not  eligible  for  surgery
ue  to  the  presence  of  severe  concomitant  diseases  (heart
isease,  kidney  disease,  etc.).
Our  study  has  several  limitations,  including  the  lack  of
 control  group.  This  may  have  masked  the  impairment
aused  by  the  natural  course  of  PD.  We  included  a  group
f  retrospectively  selected  patients  to  analyse  the  num-
er  of  patients  with  PD  developing  dementia  after  5 years.
ther  limitations  include  the  small  sample  size  and  the  fact
hat  20%  of  patients  were  lost  to  follow-up,  mainly  due  to
eath  or  systemic  diseases.  However,  the  few  5-year  follow-
p  studies  in  the  literature  that  analyse  cognitive  function,
s  well  as  the  homogeneity  of  our  sample  and  the  fact  that
ll  patients  were  evaluated  by  the  same  neuropsychologist,
onfer  consistency  and  validity  to  our  results.
In  conclusion,  significant  impairment  of  verbal  function
an  be  observed  one  year  after  surgery  and  increases  over
he  5  years  following  the  procedure,  although  this  cannot
e  explained  by  surgery  exclusively.  Degeneration  caused
y  PD  itself  may  explain  visuospatial  and  learning  impair-
ent.  Improvements  in  motor  function  are  less  pronounced
t  5  years.  Performance  in  activities  of  daily  living  improves,
owering  the  required  doses  of  antiparkinson  drugs,  which  in
urn  reduces  the  frequency  of  motor  complications.
unding
his  study  was  partially  funded  by  research  grant  INT-BC-
016-1  from  Biocruces  Bizkaia  Health  Research  Institute.
onflicts of  interest
he  authors  have  no  conflicts  of  interest  to  declare.
eferences
1. Deep-Brain Stimulation for Parkinson’s Disease Study Group.
Deep-brain stimulation of the subthalamic nucleus or the pars
interna of the globus pallidus in Parkinson’s disease. N Engl J2. Benabid AL, Chabardes S, Mitrofanis J, Pollak P. Deep brain
stimulation of the subthalamic nucleus for the treatment of
Parkinson’s disease. Lancet Neurol. 2009;8:67—81.
ncti
1
1
1
2
2
2
2
2
2
2
2
2
2
3Long-term  impact  of  subthalamic  stimulation  on  cognitive  fu
3. Alegret M, Junque C, Valldeoriola F, Vendrell P, Pilleri M, Rumià
J, et al. Effects of bilateral subthalamic stimulation on cognitive
function in Parkinson disease. Arch Neurol. 2001;58:1223—7.
4. Heo JH, Lee KM, Paek SH, Kim MJ, Lee JY, Kim JY, et al.
The effects of bilateral subthalamic nucleus deep brain
stimulation (STN DBS) on cognition in Parkinson disease. J Neu-
rol Sci. 2008;273:19—24.
5. Parsons TD, Rogers SA, Braaten AJ, Woods SP, Troster AI.
Cognitive sequelae of subthalamic nucleus deep brain stimu-
lation in Parkinson’s disease: a meta-analysis. Lancet Neurol.
2006;5:578—88.
6. Jahanshahi M, Ardouin CM, Brown RG, Rothwell JC, Obeso J,
Albanese A, et al. The impact of deep brain stimulation on exec-
utive function in Parkinson’s disease. Brain. 2000;123:1142—54.
7. Pillon B, Ardouin C, Damier P, Krack P, Houeto JL, Klinger
H, et al. Neuropsychological changes between ‘‘off’’ and
‘‘on’’ STN or GPi stimulation in Parkinson’s disease. Neurology.
2000;55:411—8.
8. Witt K, Pulkowski U, Herzog J, Lorenz D, Hamel W,  Deuschl
G, et al. Deep brain stimulation of the subthalamic nucleus
improves cognitive flexibility but impairs response inhibition in
Parkinson disease. Arch Neurol. 2004;61:697—700.
9. Lezcano E, Gómez-Esteban JC, Zarranz JJ, Lambarri I, Madoz
P, Bilbao G, et al. Improvement in quality of life in patients
with advanced Parkinson’s disease following bilateral deep-
brain stimulation in subthalamic nucleus. Eur J Neurol.
2004;11:451—4.
10. Lagrange E, Krack P, Moro E, Ardouin C, Van Blercom N,
Chabardes S, et al. Bilateral subthalamic nucleus stimula-
tion improves health-related quality of life in PD. Neurology.
2002;59:1976—8.
11. Cury RG, Galhardoni R, Fonoff ET, Dos Santos Ghilardi MG,
Fonoff F, Arnaut D, et al. Effects of deep brain stimulation
on pain and other nonmotor symptoms in Parkinson disease.
Neurology. 2014;83:1403—9.
12. Moro E, Lozano AM, Pollak P, Agid Y, Rehncrona S, Volkmann
J, et al. Long-term results of a multicenter study on subthala-
mic and pallidal stimulation in Parkinson’s disease. Mov Disord.
2010;25:578—86.
13. Lezcano E, Gómez-Esteban JC, Tijero B, Bilbao G, Lambarri I,
Rodriguez O, et al. Long-term impact on quality of life of sub-
thalamic nucleus stimulation in Parkinson’s disease. J Neurol.
2016;263:895—905.
14. Schupbach WM, Chastan N, Welter ML, Houeto JL, Mesnage V,
Bonnet AM, et al. Stimulation of the subthalamic nucleus in
Parkinson’s disease: a 5 year follow up. J Neurol Neurosurg
Psychiatry. 2005;76:1640—4.
15. Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin
C, et al. Five-year follow-up of bilateral stimulation of the sub-
thalamic nucleus in advanced Parkinson’s disease. N Engl J Med.
2003;349:1925—34.
16. Contarino MF, Daniele A, Sibilia AH, Romito LM, Bentivoglio
AR, Gainotti G, et al. Cognitive outcome 5 years after bilat-
eral chronic stimulation of subthalamic nucleus in patients
with Parkinson’s disease. J Neurol Neurosurg Psychiatry.
2007;78:248—52.
3on  581
7. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE.
Systematic review of levodopa dose equivalency reporting in
Parkinson’s disease. Mov Disord. 2010;25:2649—53.
8. Funkiewiez A, Ardouin C, Caputo E, Krack P, Fraix V, Klinger H,
et al. Long term effects of bilateral subthalamic nucleus stimu-
lation on cognitive function, mood, and behaviour in Parkinson’s
disease. J Neurol Neurosurg Psychiatry. 2004;75:834—9.
9. Aybek S, Gronchi-Perrin A, Berney A, Chiuvé SC, Villemure JG,
Burkhard PR, et al. Long-term cognitive profile and incidence
of dementia after STN-DBS in Parkinson’s disease. Mov Disord.
2007;22:974—81.
0. Fasano A, Romito LM, Daniele A, Piano C, Zinno M, Ben-
tivoglio AR, et al. Motor and cognitive outcome in patients with
Parkinson’s disease 8 years after subthalamic implants. Brain.
2010;133:2664—76.
1. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H,
Kragh-Sorensen P. Risk of dementia in Parkinson’s dis-
ease: a community-based, prospective study. Neurology.
2001;56:730—6.
2. Abboud H, Floden D, Thompson NR, Genc G, Oravivattanakul S,
Alsallom F, et al. Impact of mild cognitive impairment on out-
come following deep brain stimulation surgery for Parkinson’s
disease. Parkinsonism Relat Disord. 2015;21:249—53.
3. Somme JH, Gomez-Esteban JC, Molano A, Tijero B, Lezcano E,
Zarranz JJ. Initial neuropsychological impairments in patients
with the E46K mutation of the alpha-synuclein gene (PARK 1). J
Neurol Sci. 2011;310:86—9.
4. Smith KM, O’Connor M, Papavassiliou E, Tarsy D, Shih LC. Phone-
mic  verbal fluency decline after subthalamic nucleus deep brain
stimulation does not depend on number of microelectrode
recordings or lead tip placement. Parkinsonism Relat Disord.
2014;20:400—4.
5. Bejjani BP, Damier P, Arnulf I, Thivard L, Bonnet AM, Dormont
D, et al. Transient acute depression induced by high-frequency
deep-brain stimulation. N Engl J Med. 1999;340:1476—80.
6. Kim HJ, Jeon BS, Paek SH. Nonmotor symptoms and subthala-
mic  deep brain stimulation in Parkinson’s disease. J Mov Disord.
2015;8:83—91.
7. Castrioto A, Lhommee E, Moro E, Krack P. Mood and behavioural
effects of subthalamic stimulation in Parkinson’s disease.
Lancet Neurol. 2014;13:287—305.
8. Gervais-Bernard H, Xie-Brustolin J, Mertens P, Polo G, Klinger
H, Adamec D, et al. Bilateral subthalamic nucleus stimulation
in advanced Parkinson’s disease: five year follow-up. J Neurol.
2009;256:225—33.
9. Ostergaard K, Aa Sunde N. Evolution of Parkinson’s disease dur-
ing 4 years of bilateral deep brain stimulation of the subthalamic
nucleus. Mov Disord. 2006;21:624—31.
0. Gómez-Esteban JC, Tijero B, Somme J, Ciordia R, Berganzo K,
Rouco I, et al. Impact of psychiatric symptoms and sleep disor-
ders on the quality of life of patients with Parkinson’s disease.
J Neurol. 2011;258:494—9.1. Gómez-Esteban JC, Zarranz JJ, Lezcano E, Tijero B, Luna A,
Velasco F, et al. Influence of motor symptoms upon the qual-
ity of life of patients with Parkinson’s disease. Eur Neurol.
2007;57:161—5.
